Platform study for scleroderma with lung disease
Treatments studied
Part of Lungs & breathing, Skin clinical trials.
This trial tests new treatments for people with scleroderma-related lung disease. You may be eligible if you have systemic sclerosis with lung scarring, your symptoms started within the last 7 years, and you have not had certain prior treatments or transplants.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and have been diagnosed with systemic sclerosis (scleroderma).
- Your first symptoms (other than Raynaud’s) started 7 years ago or less.
- You have lung scarring (interstitial lung disease) seen on a CT scan, and your lung function tests show certain minimum values (FVC at least 45% and DLCO at least 30% of predicted).
- You do not have active infections, kidney crisis in the last 6 months, or recent use of specific medications like rituximab, tocilizumab, or other biologics.
- You have not had a stem cell or organ transplant, or certain other cell-depleting therapies.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called CABA-201, which uses your own immune cells to target and calm the overactive immune system causing scleroderma. It aims to reduce symptoms and slow or stop the disease's progression.
This registry collects health and breathing test information from adults with autoimmune-related lung scarring (interstitial lung disease) diagnosed recently. It helps researchers better understand who has this condition and how it changes over time.
This study tests a new medicine called nerandomilast to see if it can help people with lung scarring caused by autoimmune rheumatic diseases like rheumatoid arthritis or scleroderma. The goal is to slow down lung damage and improve breathing.
This trial tests if nerandomilast can help people with systemic sclerosis, a disease that can affect the skin and lungs. It may be an option for those with active disease and reduced lung function.
This study tests whether a new drug called nerandomilast can slow down scarring in the lungs for people with certain types of fibrosing interstitial lung disease (a condition where lung tissue becomes thick and scarred). You may qualify if you have lung scarring that is getting worse and haven't tried this or similar drugs before.
This trial tests whether combining two drugs, rituximab and mycophenolate mofetil, is safe and works better than standard care for lung scarring caused by scleroderma. It may be an option if your lung disease is severe or getting worse.
Hear when a new Interstitial Lung Disease Due to Systemic Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.